PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society

 

 

NES-ZIONA, Israel, Sept. 27 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that data from its longer-acting human growth hormone (hGH-CTP) program will be featured in an oral scientific presentation at the 5th International Congress Of The Growth Hormone Research Society (GRS) and IGF Society on October 4, 2010.

PROLOR is developing hGH-CTP to provide growth hormone-deficient adults and children with therapy that requires only once-weekly or bi-monthly injections, rather than the multiple injections per week required by current growth hormone regimens.  hGH-CTP is currently in a Phase II clinical trial following a successful Phase I trial that showed that hGH-CTP met all safety and tolerability endpoints and could potentially be effective when injected just twice per month.  

The hGH-CTP Phase II trial is a randomized, open-label, dose-finding study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected either weekly or twice-monthly in patients with growth hormone deficiency who currently receive daily injections of growth hormone.  The trial is being conducted at up to 14 sites in six countries.  PROLOR expects to complete the Phase II trial in 2011.

"We are pleased to have the opportunity to present our hGH-CTP program to the leading growth hormone academic and industry researchers from around the globe who will be participating in this important meeting," noted Dr. Abraham Havron, CEO of PROLOR.  "We are especially honored to be one of only three companies selected to participate in the scientific program.  This Congress provides us a valuable forum for raising awareness of our longer-acting growth hormone product, which has the potential to provide important benefits to the many patients requiring growth hormone therapy."

PROLOR's hGH-CTP presentation is scheduled for 10:45 am ET on October 4, 2010.  The 5th International Congress will be held at the Sheraton New York Hotel in New York City from October 3-6, 2010.

For more information about the conference, visit http://www.5grs-igf.org.    

About The Growth Hormone Research Society

The Growth Hormone Research Society (GRS) was founded in 1992 to provide a forum for the study and exchange of ideas on all aspects of growth hormone physiology, and diseases involving abnormalities of the GH axis.  With over 400 members from more than 30 countries, the society represents a unique international body composed of clinicians, scientists, educators, and students.  These individuals are committed to the advancement and dissemination of research and education on a milieu of medical and biological topics related to GH.  The GRS holds biannual meetings in conjunction with its sister society, the IGF Society.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as GLP-1 and other therapeutic peptides.  For more information on PROLOR, visit http://www.prolor-biotech.com.

Safe Harbor Statement :  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.


 

 
 

PROLOR CONTACT:

MEDIA CONTACT:

 

Shai Novik, President

Barbara Lindheim

 

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

 

Tel: +1 866 644-7811

+1 212 918-4650

 

Email: shai@prolor-biotech.com


 
 

 

 
 
   


 

SOURCE PROLOR Biotech, Inc.

CONTACT: Shai Novik, President, PROLOR Biotech, Inc., +1-866-644-7811, shai@prolor-biotech.com, or MEDIA: Barbara Lindheim, GendeLLindheim BioCom Partners, +1-212-918-4650
 

Web Site: http://www.prolor-biotech.com
 

Posted: September 2010

View comments

Hide
(web1)